SCHEMBL13699155

SCHEMBL13699155

CCc1cc(NC(=O)NC(CC)CC)ccc1Oc1ccc(NC(=O)c2ccc(OC3CC4CCC(C3)N4C)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.41
CYP3A4 P08684 1/20 0.38
TTK P33981 1/20 0.38
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38
OPRK1 P41145 1/20 0.38
MCHR1 Q99705 3/20 0.37
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
MCHR2 Q969V1 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2D6 P10635 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699250 0.94 PKM (0.42) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699163 0.92 PKM (0.41) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699285 0.92 PKM (0.41) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699277 0.91 PKM (0.45) PKMMCHR1TAS1R3TAS1R1NPC1
SCHEMBL13699147 0.91 PKM (0.41) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699146 0.91 PNLIP (0.45) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699204 0.91 PKM (0.48) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699150 0.90 PKM (0.40) PKMCYP3A4TTKAURKBINCENP
SCHEMBL13699145 0.89 EPHX2 (0.43) PKMMEN1KMT2ACYP2D6
SCHEMBL13699133 0.86 PKM (0.45) PKMMCHR1TAS1R3TAS1R1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885CYP3A4 2140/4885TTK 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.